CTLA4 and neoplasm: Taking into consideration that all different in vivo efficacy and tumor-immune phenotyping results, the higher expression levels of CTLA-4 in phenotyping were associated with more effective treatment of the anti-CTLA-4 antibody, implying that the effect of immunotherapy is mainly dominated by tumor-immune microenvironment with depending on tumor growth phases regardless of tumor type.